UPDATE 1-Eisai say FDA approves higher dose Aricept

NEW YORK, July 23 (BestGrowthStock) – Eisai Co (4523.T: ) and Pfizer
Inc (PFE.N: ) said they won U.S. regulatory approval for a higher
dose once-daily version of Aricept, a drug that treats
Alzheimer disease.

Eisai, Japan’s No. 4 drugmaker, said in March it expected
annual U.S. sales of the drug, its flagship product, to fall 60
percent to $800 million from $2 billion between 2011 and 2013
with the expiration of its patent for the drug looming.
[ID:nTOE62306Z]

The U.S. Federal Drug Administration approved a 23 mg
tablet version of the drug, which treats moderate-to-severe
Alzheimer’s. About 3.5 million Americans over the age of 65
suffer from the disease.

Stock Market Advice

(Reporting by Phil Wahba; editing by Carol Bishopric)

UPDATE 1-Eisai say FDA approves higher dose Aricept